INTRODUCTION AND OBJECTIVES: Primary whole gland cryotherapy has been shown to be an effective treatment for clinically localized prostate cancer with multiple RCTs demonstrating similar rates of biochemical recurrence (BCR) compared to radiation therapy. While several studies have assessed risk factors of BCR after radical prostatectomy this data is limited for patients undergoing primary whole gland cryotherapy. We therefore sought to determine specific disease, perioperative and early postoperative variables that modify risk of BCR.
METHODS: We performed a retrospective analysis of patients who received primary whole gland cryotherapy between 2007 and 2017 at a large tertiary referral center. The primary outcome was BCR, defined as per the Phoenix criteria (PSA nadir þ 2.0 ng/ml). Cox proportional hazard regression analysis was used to test models of variables predicting BCR. The Akaike information criteria (AIC) method was used to model the optimal PSA nadir cut-off for risk of BCR.
RESULTS: 350 of 391 patients who received cryotherapy during the study period at our institution were identified as having received primary whole gland cryotherapy. CONCLUSIONS: We have identified several robust disease specific and early postoperative predictors of BCR. These risk factors may be used in counselling patients before their cryoablation as well as for potentially selecting patients who may require closer follow-up based on PSA nadir 0.7 or higher risk features.
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MP78-03 TUMOR CONTROL OUTCOMES OF SALVAGE CRYOTHERAPY FOR RADIORECURRENT PROSTATE CANCER AT MEDIAN 12 YEARS FOLLOW-UP
Shiva Nair*, London, Canada; Max Peters, Utrecht, Netherlands; Haider Abed, London, Canada; Jochem van der Voort van Zyp, Marieke van Son, Utrecht, Netherlands; Joseph Chin, London, Canada INTRODUCTION AND OBJECTIVES: Local prostate cancer recurrences after primary radiotherapy can occur, even with doseescalation schedules. Salvage therapies can defer the use of subsequent systemic therapies, which tend to be non-curative with significant side-effects. The results of a large cohort of salvage cryotherapy (sCryo) patients is presented here with median 12 years follow-up.
METHODS: Patients treated with salvage cryotherapy from 1995 to 2004 were included. Patients had histological confirmation of local recurrence with a transrectal ultrasound guided biopsy (except 2 patients). Metastatic screen with CT and radionucleotide bone scan were negative. Pre-salvage data was collected to predict oncological outcomes. Kaplan-Meier analysis was performed to assess overall survival (OS), prostate cancer specific survival (PCSS), metastases free survival (MFS), development of castrate resistant prostate cancer (CRPC) and biochemical disease free survival (BDFS) according to the Phoenix definition. Cox-regression was used to assess predictive factors for OS, PCSS, CRPC and MFS.
RESULTS: 187 patients with completed data on were treated with sCryo. Median follow-up was 149 months. Median age before salvage was 71 years (interquartile range [IQR] 66-74), median PSA pre-salvage 11 ng/ml (IQR 7.8-18.7). Twelve-year OS was 56% (CI 49-64). Pre-salvage age and PSA nadir post-salvage predicted overall mortality. Twelve-year PCSS was 81% (CI 75-88). Preradiation Gleason score 8-10 and stage (T3a-T4), pre-salvage PSA and PSA-nadir post-salvage cryotherapy predicted PCSS in multivariable analysis. Twelve-year freedom from CRPC was 80%, . Multivariate analysis showed primary stage and PSA-nadir post-salvage treatment to be significant predictors of CRPC. Twelveyear MFS was 78% (CI 71-85). T3a-T4 and PSA-nadir post-salvage cryotherapy predicted metastases in multivariable analysis. Median time to biochemical recurrence was 58 months (CI 44-79); with median time to ADT 101 months (CI 65-NA). 91 patients (48.7%) were ADT free at end of follow up.
CONCLUSIONS: Salvage cryotherapy for localized radiorecurrent prostate cancer can provide durable response, with PCSS and MFS of approximately 80% at 12 years. OS, PCSS, CRPC and MFS are affected by a combination of primary T-stage, pre-radiation Gleason score, pre-salvage PSA and PSA-nadir post-salvage. Salvage treatment can achieve ADT free status in selected patients and delay in those who subsequently developed systemic disease.
Source of Funding: None
MP78-04 PREDICTING PROSTATE CANCER FOCAL THERAPY ELIGIBILITY WITH MACHINE LEARNING
Steve Zhou*, Alan Priester, Rajiv Jayadevan, Jason Yang, David Johnson, Alex Raman, Karthik Sarma, Corey Arnold, Jorge Ballon, Shyam Natarajan, Leonard Marks, Los Angeles, CA INTRODUCTION AND OBJECTIVES: Focal therapies such as hemi-gland ablation (HGA) are evolving treatment options for prostate cancer. However, limitations in current diagnostics-biopsy Gleason score, biopsy-determined laterality, MRI, and PSA-may result in improper candidate selection and lead to suboptimal oncologic control. In machine learning, linear classifiers are simple but powerful tools that use logistic regression models to calculate probability, sorting data into one of multiple possible classes. We trained a linear classifier to better predict patient HGA eligibility using spatial information from fusion biopsy.
METHODS: We identified patients who received fusion biopsy and radical prostatectomy (RP) at a single institution between May 2011 and March 2018. In addition to standard clinical features (Fig 1A: III-V), we extracted fusion biopsy features related to core and target locations (Fig 1A: I, II) . These features were used to train a linear classifier to classify patients by HGA eligibility (unilateral intermediate-risk cancer on RP) in a randomized set of patients. We assessed the resulting algorithm's predictive performance in an independent set of test data, verified with 5-fold cross-validation. The evaluation metric was the area under the curve (AUC) statistic. Accuracy was compared to current eligibility criteria (biopsy-proven unilateral intermediate-risk cancer).
RESULTS: Cross-validation was performed with 144 patients partitioned into 5 data blocks, each block acting once as a test set for an algorithm instance trained by the other 4. The 5 folds yielded reproducible receiver operator characteristic curves with a mean AUC of 0.83AE0.07 on test sets (Fig 1B) . The 5 most predictive features are summarized in Fig 1A. Model accuracy was 76% compared to 67% with current criteria (p[0.03); sensitivity was 68% compared to 44% (p[0.006) . Matching sensitivity to that of current criteria, the model's positive predictive value was 88% compared to 73% (Fig 1B, p[0.08) . In other words, in this dataset, 27% of patients selected by current criteria harbored undetected advanced disease for which HGA is insufficient: this incidence is halved when candidates are vetted by our model. CONCLUSIONS: A machine learning classifier, trained with fusion biopsy data, outperforms current eligibility criteria in accurately predicting HGA eligibility.
